slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 88,651-88,680
Pages 3,683
Rows per page 30
Component
88,651-88,680 of 110,471
12
Kering | Mergers and Acquisitions Presentation Deck | 15 slidesKering | Mergers and Acquisitions Presentation Deck | 15 slides · Kering
Deck Investment bank 1 hit
03
The slide uses a split-layout with a company profile on the left and a list of key accomplishments on the right.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
08
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
10
The slide uses a biological pathway diagram to illustrate the mechanism of action and a callout box for the therapeutic thesis.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
20
The slide uses individual patient data points (AD-1 to AD-7, HS-1 to HS-12) to show consistent downregulation across cohorts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
28
Includes clinical efficacy table and RNAseq biomarker reduction chart.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
30
The table compares KT-474 (Part C) at Day 28 and 42 against external benchmarks at Week 4. Includes extensive footnote citations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
32
Data presented as mean change from baseline with 90% CI. Includes table of mean values for delta QTc and absolute QTc.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
33
The slide uses color-coded text (orange) to emphasize key positive outcomes within the bullet points.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
35
The diagram illustrates the signaling pathways (TLR, IL-1R, B Cell Receptor) and the specific points of intervention (red asterisks) for the therapy.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
Includes a disclaimer/footnote regarding patient population and MYD88 mutation status.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
42
Includes a table of prevalence/incidence for specific oncology indications and a biological pathway diagram.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
45
Clinical trial safety data table showing patient counts and percentages for specific adverse events.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
47
The slide presents clinical trial results for KT-333, comparing degradation percentages across three dose levels (DL1, DL2, DL3) over two cycles.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
48
Includes bar charts for SAA/CRP reduction, a longitudinal line chart for biomarker changes, and a scatter plot showing correlation between STAT3 and SOCS3 changes.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
49
DL1-3 refers to dose levels 1-3. PK = Pharmacokinetics, PD = Pharmacodynamics, DLT = Dose-Limiting Toxicity, SAE = Serious Adverse Event.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
52
Includes a biological pathway diagram and Western blot data comparing a degrader (KT-253) to an inhibitor (DS-3032).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
53
Includes a table comparing clinical stage and potency metrics (IC50, DC50) across multiple competitors.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
54
Data presented as tumor volume growth curves and Kaplan-Meier survival plots.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
55
The slide presents five bar charts showing protein levels across different dosing regimens and time points.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
60
The image shows the Kymera Therapeutics team at their Nasdaq listing event.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
04
Limoneira | Investor Day Presentation Deck | 65 slidesLimoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · Attention1 hit
08
The slide uses a background image of lemons on a tree, consistent with the company's agricultural focus.Limoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · Need1 hit
13
Limoneira | Investor Day Presentation Deck | 65 slidesLimoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · NeedLoop · Quick Win Big Bet1 hit
14
Limoneira | Investor Day Presentation Deck | 65 slidesLimoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · NeedLoop · Quick Win Big Bet1 hit
16
Limoneira | Investor Day Presentation Deck | 65 slidesLimoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · NeedLoop · Quick Win Big Bet1 hit
24
Limoneira | Investor Day Presentation Deck | 65 slidesLimoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · Satisfaction1 hit
25
Uses a before-after-bridge structure to show the impact of a $25M investment.Limoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · Satisfaction1 hit